Skip to main content
Erschienen in: European Radiology 12/2022

03.06.2022 | Magnetic Resonance

Transient severe motion artifacts on gadoxetic acid–enhanced MRI: risk factor analysis in 2230 patients

verfasst von: Eun Bee Jang, Dong Wook Kim, Sang Hyun Choi, Seung Baek Hong, Taeyong Park, Yousun Ko, Su Jung Ham

Erschienen in: European Radiology | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine risk factors for transient severe motion (TSM) artifact on arterial phase of gadoxetic acid–enhanced MRI using a large cohort.

Methods

A total of 2230 patients who underwent gadoxetic acid–enhanced MRI was consecutively included. Two readers evaluated respiratory motion artifact on arterial phase images using a 5-point grading scale. Clinical factors including demographic data, underlying disease, laboratory data, presence of ascites and pleural effusion, and previous experience of gadoxetic acid–enhanced MRI were investigated. Univariable and multivariable logistic regression analyses were performed to determine significant risk factors for TSM. Predictive value of TSM was calculated according to the number of significant risk factors.

Results

Overall incidence of TSM was 5.0% (111/2230). In the multivariable analysis, old age (≥ 65 years; odds ratio [OR] = 2.01 [95% CI, 1.31–3.07]), high body mass index (≥ 25 kg/m2; OR = 1.76 [1.18–2.63]), chronic obstructive pulmonary disease (OR = 6.11 [2.32–16.04]), and moderate to severe pleural effusion (OR = 3.55 [1.65–7.65]) were independent significant risk factors for TSM. Presence of hepatitis B (OR = 0.66 [0.43–0.99]) and previous experience of gadoxetic acid–enhanced MRI (OR = 0.52 [0.33–0.83]) were negative risk factors for TSM. When at least one of the significant factors was present, the predictive risk was 5.7% (109/1916), whereas it was 16.3% (17/104) when at least four factors were present.

Conclusion

Knowing risk factors for transient severe motion artifact on gadoxetic acid–enhanced MRI can be clinically useful for providing diagnostic strategies more tailored to individual patients.

Key Points

Old age, high body mass index, chronic obstructive pulmonary disease, and moderate to severe pleural effusion were independent risk factors for transient severe motion artifact on gadoxetic acid–enhanced MRI.
Patients with hepatitis B or previous experience of gadoxetic acid–enhanced MRI were less likely to show transient severe motion artifact.
As the number of risk factors for transient severe motion artifact increased, the predicted risk for it also showed a tendency to increase.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRefPubMed Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459–466CrossRefPubMed
2.
Zurück zum Zitat Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed
3.
Zurück zum Zitat Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed
4.
Zurück zum Zitat Motosugi U, Ichikawa T, Morisaka H et al (2011) Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 260:446–453CrossRefPubMed Motosugi U, Ichikawa T, Morisaka H et al (2011) Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 260:446–453CrossRefPubMed
5.
Zurück zum Zitat Davenport MS, Viglianti BL, Al-Hawary MM et al (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461CrossRefPubMed Davenport MS, Viglianti BL, Al-Hawary MM et al (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461CrossRefPubMed
6.
Zurück zum Zitat Song JS, Choi EJ, Park EH, Lee JH (2018) Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method. Eur Radiol 28:1132–1139CrossRefPubMed Song JS, Choi EJ, Park EH, Lee JH (2018) Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method. Eur Radiol 28:1132–1139CrossRefPubMed
7.
Zurück zum Zitat Rimola J, Darnell A, Belmonte E et al (2020) Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. Eur Radiol 30:6694–6701CrossRefPubMed Rimola J, Darnell A, Belmonte E et al (2020) Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. Eur Radiol 30:6694–6701CrossRefPubMed
9.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRefPubMed
10.
Zurück zum Zitat Kim SY, Park SH, Wu EH et al (2015) Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses. AJR Am J Roentgenol 204:1220–1227CrossRefPubMed Kim SY, Park SH, Wu EH et al (2015) Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses. AJR Am J Roentgenol 204:1220–1227CrossRefPubMed
11.
Zurück zum Zitat Bashir MR, Castelli P, Davenport MS et al (2015) Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. Radiology 274:141–148CrossRefPubMed Bashir MR, Castelli P, Davenport MS et al (2015) Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. Radiology 274:141–148CrossRefPubMed
12.
Zurück zum Zitat Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK (2014) Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol 203:796–802CrossRefPubMed Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK (2014) Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol 203:796–802CrossRefPubMed
13.
Zurück zum Zitat Furlan A, Close ON, Borhani AA, Wu YH, Heller MT (2017) Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients. Clin Radiol 72:93.e91–93.e96CrossRef Furlan A, Close ON, Borhani AA, Wu YH, Heller MT (2017) Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients. Clin Radiol 72:93.e91–93.e96CrossRef
14.
Zurück zum Zitat Kanki A, Tamada T, Abe T, Ikenaga H, Yoshida K, Ito K (2018) Relationship between transient severe motion of the liver in gadoxetic acid or iodinated contrast agent-enhanced imaging and arterial oxygen saturation and heart rate changes. Magn Reson Imaging 53:77–81CrossRefPubMed Kanki A, Tamada T, Abe T, Ikenaga H, Yoshida K, Ito K (2018) Relationship between transient severe motion of the liver in gadoxetic acid or iodinated contrast agent-enhanced imaging and arterial oxygen saturation and heart rate changes. Magn Reson Imaging 53:77–81CrossRefPubMed
15.
Zurück zum Zitat Motosugi U, Bannas P, Bookwalter CA, Sano K, Reeder SB (2016) An investigation of transient severe motion related to gadoxetic acid-enhanced MR imaging. Radiology 279:93–102CrossRefPubMed Motosugi U, Bannas P, Bookwalter CA, Sano K, Reeder SB (2016) An investigation of transient severe motion related to gadoxetic acid-enhanced MR imaging. Radiology 279:93–102CrossRefPubMed
16.
Zurück zum Zitat Ringe KI, von Falck C, Raatschen HJ, Wacker F, Hinrichs J (2018) Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI-influence of different contrast agent application protocols. PLoS One 13:e0200887CrossRefPubMedPubMedCentral Ringe KI, von Falck C, Raatschen HJ, Wacker F, Hinrichs J (2018) Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI-influence of different contrast agent application protocols. PLoS One 13:e0200887CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Vietti Violi N, Argiriadi P, Rosen A et al (2020) Gadoxetate disodium-enhanced MRI: assessment of arterial phase artifacts and hepatobiliary uptake in a large series. Eur J Radiol 132:109313CrossRefPubMed Vietti Violi N, Argiriadi P, Rosen A et al (2020) Gadoxetate disodium-enhanced MRI: assessment of arterial phase artifacts and hepatobiliary uptake in a large series. Eur J Radiol 132:109313CrossRefPubMed
18.
Zurück zum Zitat Well L, Rausch VH, Adam G, Henes FO, Bannas P (2017) Transient severe motion artifact related to gadoxetate disodium-enhanced liver MRI: frequency and risk evaluation at a German institution. Rofo 189:651–660CrossRefPubMed Well L, Rausch VH, Adam G, Henes FO, Bannas P (2017) Transient severe motion artifact related to gadoxetate disodium-enhanced liver MRI: frequency and risk evaluation at a German institution. Rofo 189:651–660CrossRefPubMed
19.
Zurück zum Zitat Hayashi T, Saitoh S, Tsuji Y et al (2015) Influence of gadoxetate disodium on oxygen saturation and heart rate during dynamic contrast-enhanced MR imaging. Radiology 276:756–765CrossRefPubMed Hayashi T, Saitoh S, Tsuji Y et al (2015) Influence of gadoxetate disodium on oxygen saturation and heart rate during dynamic contrast-enhanced MR imaging. Radiology 276:756–765CrossRefPubMed
20.
Zurück zum Zitat Wiesner R, Edwards E, Freeman R et al (2003) Model for End-stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 124:91–96CrossRefPubMed Wiesner R, Edwards E, Freeman R et al (2003) Model for End-stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 124:91–96CrossRefPubMed
21.
Zurück zum Zitat Moore KP, Wong F, Gines P et al (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38:258–266CrossRefPubMed Moore KP, Wong F, Gines P et al (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38:258–266CrossRefPubMed
22.
Zurück zum Zitat Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR (2014) Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology 271:426–434CrossRefPubMed Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR (2014) Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology 271:426–434CrossRefPubMed
23.
Zurück zum Zitat Davenport MS, Caoili EM, Kaza RK, Hussain HK (2014) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology 272:123–131CrossRefPubMed Davenport MS, Caoili EM, Kaza RK, Hussain HK (2014) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology 272:123–131CrossRefPubMed
24.
Zurück zum Zitat Shah MR, Flusberg M, Paroder V, Rozenblit AM, Chernyak V (2017) Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents. Clin Imaging 41:23–27CrossRefPubMed Shah MR, Flusberg M, Paroder V, Rozenblit AM, Chernyak V (2017) Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents. Clin Imaging 41:23–27CrossRefPubMed
25.
Zurück zum Zitat O’Donnell DE, Revill SM, Webb KA (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:770–777CrossRefPubMed O’Donnell DE, Revill SM, Webb KA (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:770–777CrossRefPubMed
26.
Zurück zum Zitat Kanwal F, Singal AG (2019) Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 157:54–64CrossRefPubMed Kanwal F, Singal AG (2019) Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 157:54–64CrossRefPubMed
27.
Zurück zum Zitat Gutzeit A, Matoori S, Froehlich JM et al (2016) Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command. Eur Radiol 26:2714–2722CrossRefPubMed Gutzeit A, Matoori S, Froehlich JM et al (2016) Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command. Eur Radiol 26:2714–2722CrossRefPubMed
28.
Zurück zum Zitat Min JH, Kim YK, Kang TW et al (2018) Artifacts during the arterial phase of gadoxetate disodium-enhanced MRI: multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging. Eur Radiol 28:3335–3346CrossRefPubMed Min JH, Kim YK, Kang TW et al (2018) Artifacts during the arterial phase of gadoxetate disodium-enhanced MRI: multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging. Eur Radiol 28:3335–3346CrossRefPubMed
29.
Zurück zum Zitat Ikeno H, Kobayashi S, Kozaka K et al (2020) Relationship between the degree of abdominal wall movement and the image quality of contrast-enhanced MRI: semi-quantitative study especially focused on the occurrence of transient severe motion artifact. Jpn J Radiol 38:165–177CrossRefPubMed Ikeno H, Kobayashi S, Kozaka K et al (2020) Relationship between the degree of abdominal wall movement and the image quality of contrast-enhanced MRI: semi-quantitative study especially focused on the occurrence of transient severe motion artifact. Jpn J Radiol 38:165–177CrossRefPubMed
30.
Zurück zum Zitat Luetkens JA, Kupczyk PA, Doerner J et al (2015) Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol 25:3207–3213CrossRefPubMed Luetkens JA, Kupczyk PA, Doerner J et al (2015) Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol 25:3207–3213CrossRefPubMed
Metadaten
Titel
Transient severe motion artifacts on gadoxetic acid–enhanced MRI: risk factor analysis in 2230 patients
verfasst von
Eun Bee Jang
Dong Wook Kim
Sang Hyun Choi
Seung Baek Hong
Taeyong Park
Yousun Ko
Su Jung Ham
Publikationsdatum
03.06.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 12/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08885-2

Weitere Artikel der Ausgabe 12/2022

European Radiology 12/2022 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.